Lotus Pharmaceutical and Formycon Enter into a Strategic Partnership to Commercialize FYB203/Ahzantive (Biosimilar, Eylea) in APAC

Shots:

• Formycon has signed an exclusive license agreement with Lotus Pharmaceutical to commercialize FYB203/Ahzantive in APAC countries, including Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, Vietnam, and Hong Kong. Additionally, Formycon will supply the finished product to Lotus
• As per the agreement, Klinge will receive upfront and milestone payments, along with royalties on Lotus’ net sales. Formycon will participate in Klinge’s income at a mid-single to low-double-digit percentage
• In June 2024, the FDA approved the aflibercept biosimilar FYB203, followed by EC approval in Jan 2025. Formycon and Lotus are preparing regulatory submissions in APAC countries

Ref: Formycon | Image: Lotus & Formycon

Related News:- Formycon Reports the EC’s Approval of FYB203 (Biosimilar, Eylea) Under the Brand Names Ahzantive and Baiama

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com